Armistice Capital’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

Armistice Capital’s Portfolio BCTXW Stock Details BCTXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,000	Closed	-$1.88K	–	340
2025 Q2	$1.88K	Hold	25,000	–	–	﹤0.01%	201
2025 Q1	$2.55K	Sell	25,000 -350,000	-93%	-$48.5K	﹤0.01%	221
2024 Q4	$109K	Hold	375,000	–	–	﹤0.01%	203
2024 Q3	$154K	Hold	375,000	–	–	﹤0.01%	226
2024 Q2	$101K	Hold	375,000	–	–	﹤0.01%	222
2024 Q1	$510K	Hold	375,000	–	–	0.01%	198
2023 Q4	$938K	Hold	375,000	–	–	0.01%	178
2023 Q3	$926K	Hold	375,000	–	–	0.01%	147
2023 Q2	$938K	Sell	375,000 -1	-0%	-$3	0.01%	161
2023 Q1	$1.11M	Buy	375,001 +1	+0%	+$3	0.02%	135
2022 Q4	$772K	Hold	375,000	–	–	0.01%	137
2022 Q3	$1.08M	Hold	375,000	–	–	0.02%	136
2022 Q2	$975K	Hold	375,000	–	–	0.02%	127
2022 Q1	$1.95M	Hold	375,000	–	–	0.04%	100
2021 Q4	$1.76M	Hold	375,000	–	–	0.03%	123
2021 Q3	$1.78M	Hold	375,000	–	–	0.03%	117
2021 Q2	$675K	Sell	375,000 -45,536	-11%	-$56.8K	0.01%	111
2021 Q1	$450K	Buy	+420,536	New	+$412K	0.01%	108

Other funds holding BCTXW

RAM

Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $808M AUM 51.1% 1-Year Est. Return

Armistice Capital's BCTXW Position: Q3 2025 in Review

Armistice Capital sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q3 2025, closing a stake of 25,000 shares — an estimated $1.88K sold.

Armistice Capital first reported a position in BCTXW in Q1 2021 and held it in 18 quarters. The position peaked at $1.95M in Q1 2022. 3 funds tracked by Wall St. Rank hold BCTXW as of Q3 2025.

Armistice Capital reported no remaining BriaCell Therapeutics Corp Warrant position as of Q3 2025 after selling out during the quarter.
Armistice Capital sold 25,000 BriaCell Therapeutics Corp Warrant shares in Q3 2025, an estimated $1.88K.
Armistice Capital first reported a position in BriaCell Therapeutics Corp Warrant in Q1 2021 and held it in 18 quarters.
Armistice Capital's BriaCell Therapeutics Corp Warrant position peaked at $1.95M in Q1 2022.
3 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.